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* DR distribution determined by PCR-SSO [10].
Table 1. Distribution of relevant HLA antigens (typed by poly-
merase chain reaction sequence-specific oligonucleotides [peR-
SSO])in Swiss patients with alveolar echinococcosis and in healthy
Caucasian controls.
cent assay [9]. The relevant distribution ofHLA-DR antigens in
patients with AE versus a random Caucasian control group is
shown in table I.
In our patient group, the frequency of HLA-DR 13
(DRBI*1301/1302) antigen was significantly increased (pa-
tients, 34.4%;controls, 13.6%; x2 = 7.0, P = .008). The associa-
tion between an HLA antigen and susceptibility to disease after
infection with E. multilocularis was highly significant. Sub-
grouping of patients with respect to individual clinical status and
course provided more insight into the distribution of the respec-
tive DRI3. In the group of inoperable patients, 2 (12%) of 14
expressed DR 13 as did 4 (40%) of 10 of those who had partial
surgery and 6 (75%) of 8 who had radical resection. Our primary
finding was that persons expressing DR 13 develop AE with a
much higher frequency (and a relative risk factor of 5.7) than
will persons not expressing DR 13. By subgrouping patients by
clinical status and course. it was obvious that once infection
resulted in disease, a DR 13 predisposition was favorable and
radical surgery was much more likely. Why this is so remains
unknown. We postulate that in patients with DR 13, due to
higher susceptibility to disease, symptoms may become manifest
at an earlier stage of infection when radical surgical resection is
more likely.
The present study also shows a reduced frequency of HLA-
DR4 antigens among patients versus controls (patients, 15.6%;
controls, 41.3%; X2 = 6.5; P = .0 I; protection factor, 0.6). Al-
though not highly significant, this finding and knowing from
previous epidemiologic studies that a certain portion of persons
infected with E. multilocularis will not develop disease [I], or
will cast off organisms spontaneously at an early stage [4], pro-
vides the rationale for further HLA-DR studies in families of
patients at high risk of infection, such as native Yupik popula-
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Association between HLA-DR!3 and Susceptibility to
Alveolar Echinococcosis
Colleagues-Alveolar echinococcosis (AE), caused by infec-
tion with the larval stage of the small fox tapeworm Echinococ-
cus niultilocularis. is one of the most lethal helminthic infections
in humans. Its pathology and high mortality rate (56%-94% in
untreated cases; 10%-14% after treatment and early diagnosis
[I]) are reasons for public health concern.
Prevalence among European fox populations is 35% in Swit-
zerland [2], which is similar to rates reported for some endemic
areas of France and Germany. The wide distribution of foxes
infected with egg-producing E. multilocularis may represent a
considerable potential risk for humans in densely populated re-
gions, such as Switzerland; however, despite this high preva-
lence in the definitive host, the disease in humans is relatively
rare. In Switzerland, the annual morbidity rate has been rela-
tively stable at 0.18 AE cases per 100,000 inhabitants for several
decades [I]. Similar data were reported for France, Germany,
and Austria [3].
Previous seroepidemiologic studies detected cases ofearly ac-
tive, but asymptomatic, AE and provided the first evidence of
self-healed cases of AE in humans and the presence of inactive
dead or aborted larval parasites [4], indicating the potential for
different courses of AE in humans.
Experimental infections in inbred laboratory mouse strains
have shown that susceptibility and resistance to infection with
E. multilocularis metacestode and subsequent disease may be
genetically controlled [5.6]. Our efforts to understand the mech-
anisms and genetics of susceptibility to AE have focused on the
identification ofDNA markers that segregate the disease by pop-
ulations living in endemic areas. We addressed this task by de-
termining the frequency of the lymphoid cell surface HLA-DR
proteins, which are encoded in the region of the major histocom-
patibility complex and referred to as class II antigens.
Blood samples were collected over 3 years from 32 patients
with hepatic AE. The patients were preselected for the study by
their homogeneous geographic and ethnic origin (all Swiss) and
by their clinical courses (described in detail in [7]). Clinical
courses included radical resection of the hepatic metacestode
lesion without recurrence; partial resection of the hepatic lesion.
continuous mebendazole or albendazole treatment, and regres-
sive or stationary course of disease; inoperable lesion treated
with continuous mebendazole or albendazole, and stationary or
progressive development of disease. Although the clinical
courses of disease differed, the groups matched each other in
parameters, such as average age, sex, and disease duration.
HLA-DR antigens were determined by oligotyping [8]: Leuko-
cyte DNA had DRB genes amplified by the polymerase chain
reaction. This was followed by sequence-specific hybridization
with biotinylated oligonucleotides detected in a chemolumines-
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tions ofAlaska, and for reversed elucidation ofpotential genetic
resistance markers indicating metacestode abortion [4].
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Nitric Oxide in Cerebral Malaria
Colleagues-Cerebral malaria is an important complication of
Plasmodium [alciparum infection and a major cause of infant
mortality in Africa. The pathophysiology of cerebral malaria
remains incompletely understood. Recently, a link between cy-
tokines, nitric oxide (NO), and cerebral malaria was proposed
[I, 2]. It was hypothesized that intravascular NO, induced by
tumor necrosis factor in endothelial cells and vascular smooth
muscle, diffuses through the blood-brain barrier and interferes
with neurologic function. Furthermore, NO is thought to in-
crease intracranial pressure, a common feature in cerebral ma-
laria in African children [3}, through increased vasodilatation.
Our data do not support this concept.
We studied the evolution of NO plasma concentrations in 28
African children (mean age ± SO, 4.4 ± 3 years) with cerebral
malaria in Yaounde. All children presented with unrousable
coma and P.falciparum parasitemia. Coma depth was assessed
according to the modified Glasgow coma scale for young chil-
dren [4}. Other causes of coma were excluded. After treatment
with quinine (25 mg of base/kg daily for 8 days), the clinical
outcome was favorable in 21 cases; 4 children developed neuro-
logic sequelae. Three children died: after 12 h, 3 days, and 4
days. Mean duration of coma for the 25 surviving children was
45.1 ± 31.4 h. NO plasma concentrations were measured on the
day of admission (day 1) and on days 2,3,5, and 8 (discharge).
Stable NO end products (N02 and NO]") were measured by
means of an automated procedure, as described previously [5].
On day 1, mean NO concentration in 28 children was 44.3 ±
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36.5 J.LM. Children with favorable outcome presented with a
higher mean NO concentration (49.9 ± 40.3 J.LM) than those
with neurologic sequelae (30.6 ± 15.5 J.LM) or those who died
(23.7 ± 4.6 p.M). NO concentrations were higher in children
with a coma score of 3 (n = 11; 63.2 ± 49 J.LM) than in children
with a coma score of 1 or 2 (n = 17; 32.2 ± 18.6 J.LM). These
differences were not statistically significant. NO concentrations
were negatively correlated with the duration ofcoma (Spearman
rank test, r = -.49, P < .02), indicating that the duration of
coma was significantly longer in children with NO plasma levels
<44.3 p.M than in those with NO plasma levels superior to the
mean (53.6 ± 27.5 vs. 32.4 ± 34.0 h; P < .02). No significant
correlation between NO level and platelet or white blood cell
counts, blood glucose level, parasitemia, hemoglobin level, or
body temperature was found.
We observed an increase of mean NO concentration after 24
h of quinine treatment in children with favorable outcome
(group A); in children with sequelae (group B), this was found
after 48 h. By day 3, mean NO level was higher in group A (44.2
± 50.9 p.M) than in group B (12.8 ± 3.9 J.LM)(Mann-Whitney U
test, P = .03). Similar results were observed at day 5 (62.1 ±
68.1 vs. 16.2 ± 7.1 p.M; P < .04; figure 1).
Although NO plasma concentrations are higher during cere-
bral malaria than during uncomplicated malaria attacks (unpub-
lished data), our results seem to refute the hypothesis that in-
creased NO levels are detrimental in the development of
cerebral malaria. In a murine model, N-monomethyl-L-arginine,
an inhibitor ofNO synthase, prevented neither the development
of neurologic symptoms nor the death of Plasmodium berghei-
infected mice [6, 7]. Furthermore, treatment with a competitive
NO synthase inhibitor had a deleterious effect in complicated
murine Plasmodium vinckei malaria [8]. Therefore, it has been
suggested that NO has a protective role in cerebral malaria [9}.
Further investigations are being done to confirm the protective
effectofNO in human pathology as suggested by murine models
and by our preliminary results.
